US Patent 8916195 Sustained release formulation of naltrexone
Patent 8916195 was granted and assigned to Orexigen Therapeutics on December, 2014 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 8916195 Sustained release formulation of naltrexone
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
